Related Experiment Video
Updated: Jan 31, 2026
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
Precision oncology in rare tumors: Have the orphans been adopted?
Hiba Mechahougui1, Alex Friedlaender2, Kıvanç Görgülü3
1Oncology Department, Geneva University Hospital, 1205 Geneva, Switzerland.
Abstract:
Oncology has shifted from organ- or histology-based therapy toward precision medicine, guided by molecular and immune targets. This paradigm change is especially impactful in rare cancers, which may be defined by unusual histology, anatomical site, or uncommon molecular subtypes of common tumors. The emergence of tumor-agnostic, histology-independent classifications has added new molecularly defined rare tumor groups. Biomarker-based therapies mark a turning point in personalized medicine, with several gene- and immune-targeted drugs now approved by the US Food and Drug Administration (FDA). Tissue-agnostic approvals typically rely on trials showing high response rates and durable benefit across diverse cancers driven by rare molecular alterations. This approach is crucial for the ∼200 types of histologically rare cancers, where trials in tiny patient subsets are unfeasible. Finally, the complexity and variability of tumor genomics between patients highlight the need for individualized, n-of-1 therapeutic combinations as the next step in optimizing cancer treatment.
Insights
Precision medicine is revolutionizing oncology, especially for rare cancers. Tumor-agnostic therapies targeting molecular alterations offer new hope where traditional trials are unfeasible.
Area of Science:
- Oncology
- Genomics
- Personalized Medicine
Background:
- Oncology is transitioning from organ-based treatments to precision medicine, focusing on molecular and immune targets.
- Rare cancers, characterized by unusual histology, site, or molecular subtypes, present unique challenges for treatment.
- Tumor-agnostic, histology-independent classifications are creating new molecularly defined rare tumor groups.
Purpose of the Study:
- To highlight the impact of precision medicine and biomarker-based therapies on rare cancer treatment.
- To discuss the significance of tissue-agnostic drug approvals for rare cancers.
- To emphasize the need for individualized therapeutic strategies in complex cancer genomics.
Main Methods:
- Review of the paradigm shift in oncology towards precision medicine.
- Analysis of the role of biomarker-based and tissue-agnostic therapies.
- Discussion of challenges and future directions in rare cancer treatment.
Main Results:
- Biomarker-based therapies and US Food and Drug Administration (FDA)-approved targeted drugs represent a turning point.
- Tissue-agnostic approvals, based on trials with high response rates in diverse cancers, are crucial for rare tumors.
- The complexity of tumor genomics necessitates individualized, n-of-1 therapeutic combinations.
Conclusions:
- Precision medicine, particularly biomarker-driven and tissue-agnostic approaches, is transforming rare cancer care.
- These strategies overcome limitations of traditional clinical trials in small patient subsets.
- Individualized combination therapies are the future for optimizing treatment in complex and variable tumor genomics.
Related Concept Videos
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
03:37Uncertainty in Measurement: Accuracy and Precision
01:52Accuracy and Precision
01:27The Precise Definition of a Limit
01:27Tumor Immunotherapy
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...